Feasibility of Using Molecular Docking-Based Virtual Screening for Searching Dual Target Kinase Inhibitors

Multitarget agents have been extensively explored for solving limited efficacies, poor safety, and resistant profiles of an individual target. Theoretical approaches for searching and designing multitarget agents are critically useful. Here, the performance of molecular docking to search dual-target inhibitors for four kinase pairs (CDK2-GSK3B, EGFR-Src, Lck-Src, and Lck-VEGFR2) was assessed. First, the representative structures for each kinase target were chosen by structural clustering of available crystal structures. Next, the performance of molecular docking to distinguish inhibitors from noninhibitors for each individual kinase target was evaluated. The results show that molecular docking-based virtual screening illustrates good capability to find known inhibitors for individual targets, but the prediction accuracy is structurally dependent. Finally, the performance of molecular docking to identify the dual-target kinase inhibitors for four kinase pairs was evaluated. The analyses show that molecular docking successfully filters out most noninhibitors and achieves promising performance for identifying dual-kinase inhibitors for CDK2-GSK3B and Lck-VEGFR2. But a high false-positive rate leads to low enrichment of true dual-target inhibitors in the final list. This study suggests that molecular docking serves as a useful tool in searching inhibitors against dual or even multiple kinase targets, but integration with other virtual screening tools is necessary for achieving better predictions.

[1]  Richard M. Jackson,et al.  Binding Site Similarity Analysis for the Functional Classification of the Protein Kinase Family , 2009, J. Chem. Inf. Model..

[2]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[3]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[4]  R. Atkins,et al.  Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. , 2002, Journal of the American Society of Nephrology : JASN.

[5]  Eric J. Martin,et al.  Profile-QSAR: A Novel meta-QSAR Method that Combines Activities across the Kinase Family To Accurately Predict Affinity, Selectivity, and Cellular Activity , 2011, J. Chem. Inf. Model..

[6]  R. Abagyan,et al.  Flexible ligand docking to multiple receptor conformations: a practical alternative. , 2008, Current opinion in structural biology.

[7]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2007, Nature Reviews Drug Discovery.

[8]  P. Cozzini Target Flexibility: An Emerging Consideration in Drug Discovery and Design , 2009 .

[9]  G. Barton,et al.  Multiple protein sequence alignment from tertiary structure comparison: Assignment of global and residue confidence levels , 1992, Proteins.

[10]  Boon Chuan Low,et al.  In-Silico Approaches to Multi-target Drug Discovery , 2010, Pharmaceutical Research.

[11]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[12]  Simone Sciabola,et al.  Predicting Kinase Selectivity Profiles Using Free‐Wilson QSAR Analysis. , 2008 .

[13]  Huijong Han,et al.  Discovery of a potential allosteric ligand binding site in CDK2. , 2011, ACS chemical biology.

[14]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[15]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[16]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[17]  Robert P. Sheridan,et al.  Multiple protein structures and multiple ligands: effects on the apparent goodness of virtual screening results , 2008, J. Comput. Aided Mol. Des..

[18]  R. Morphy Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.

[19]  G. Scapin Structural biology in drug design: selective protein kinase inhibitors. , 2002, Drug discovery today.

[20]  Satoshi Niijima,et al.  Dissecting Kinase Profiling Data to Predict Activity and Understand Cross-Reactivity of Kinase Inhibitors , 2012, J. Chem. Inf. Model..

[21]  Stephen R. Johnson,et al.  Trends in kinase selectivity: insights for target class-focused library screening. , 2011, Journal of medicinal chemistry.

[22]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[23]  J. Drews Drug discovery: a historical perspective. , 2000, Science.

[24]  Yuri Pevzner,et al.  Virtual Target Screening: Validation Using Kinase Inhibitors , 2012, J. Chem. Inf. Model..

[25]  Susan O'Brien,et al.  Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. , 2007, Blood.

[26]  Somesh D. Sharma,et al.  Managing protein flexibility in docking and its applications. , 2009, Drug discovery today.

[27]  Keun Woo Lee,et al.  Molecular Docking and Pharmacophore Filtering in the Discovery of Dual-Inhibitors for Human Leukotriene A4 Hydrolase and Leukotriene C4 Synthase , 2011, J. Chem. Inf. Model..

[28]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[29]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[30]  Eric J. Martin,et al.  Kinase-Kernel Models: Accurate In silico Screening of 4 Million Compounds Across the Entire Human Kinome , 2012, J. Chem. Inf. Model..

[31]  Jiri Gut,et al.  Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. , 2004, Journal of medicinal chemistry.

[32]  Zhinan Yin,et al.  A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice , 2011, The Journal of Immunology.

[33]  Y Z Chen,et al.  Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. , 2010, Molecular pharmaceutics.

[34]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[35]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[36]  Ian Collins,et al.  Measuring and interpreting the selectivity of protein kinase inhibitors , 2009, Journal of chemical biology.

[37]  P. Zarrinkar,et al.  High-throughput kinase profiling as a platform for drug discovery , 2008, Nature Reviews Drug Discovery.

[38]  R. Gozalbes,et al.  Development and experimental validation of a docking strategy for the generation of kinase-targeted libraries. , 2008, Journal of medicinal chemistry.

[39]  Jarl E. S. Wikberg,et al.  Kinome-wide interaction modelling using alignment-based and alignment-independent approaches for kinase description and linear and non-linear data analysis techniques , 2010, BMC Bioinformatics.

[40]  Robert P. Sheridan,et al.  QSAR Models for Predicting the Similarity in Binding Profiles for Pairs of Protein Kinases and the Variation of Models between Experimental Data Sets , 2009, J. Chem. Inf. Model..

[41]  Ariel Fernández,et al.  In silico drug profiling of the human kinome based on a molecular marker for cross reactivity. , 2008, Molecular pharmaceutics.

[42]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[43]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[44]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Abagyan,et al.  Systematic Exploitation of Multiple Receptor Conformations for Virtual Ligand Screening , 2011, PloS one.

[46]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[47]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[48]  S. Knapp,et al.  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.

[49]  Yan Xu,et al.  [Multi-target therapeutics and new drug discovery]. , 2009, Yao xue xue bao = Acta pharmaceutica Sinica.